Kuhnil to develop new antiulcer drug

Published: 2009-12-15 06:56:00

Updated: 2009-12-15 06:56:00

Kuhnil Pharm is making its intensive efforts to develop an investigational antiulcer drug for the treatment of gastrointestinal disturbances induced by non-steroidal anti-inflammatory drugs, the government officials said on December 8.

The Ministry of Knowledge Economy yesterday said it would ...

Fees

- Email service daily and homepage access.

$300 per month. ($3,240 per year)
5 Email holders per each company.
Anual contract base.

Latest News

Which are outstanding tetravalent vaccines even for the young?

Disease treated the most with clinical trial drugs is respiratory disorder like lung cancer

Who will be the next Pharmaceutical Safety Bureau Director?

Celltrion completes clinical trials for Remsima SC for European approval

Sales listed pharmas made in the first half of the year

TOP

BACK